Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Systematic Review

Accepted on 14 Feb 2025

Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: A systematic review and network meta-analysis

in Pharmacology of Anti-Cancer Drugs

Wenjun Quan
Hanifah Zulkifli
Norhafizah Binti Saari
Rafidah Hanim Shueb
Nazri Mustaffa

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1502931

Original Research

Accepted on 14 Feb 2025

Cyperotundone Promotes Chemosensitivity of Breast Cancer via SRSF1

in Pharmacology of Anti-Cancer Drugs

Chao Li
Lin Wang
Zhaoyun Liu
Xinzhao Wang
Luhao Sun
Xiang Song
Zhiyong Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510161

Case Report

Published on 14 Feb 2025

Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinib

in Pharmacology of Anti-Cancer Drugs

Jia-Jun Hui
Sheng-Jun Ding
Bao-Dong Qin
Ning Ding

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1525251

123 views

Original Research

Published on 14 Feb 2025

Identification of potential diagnostic targets and therapeutic strategies for anoikis-related biomarkers in lung squamous cell carcinoma using machine learning and computational virtual screening

in Pharmacology of Anti-Cancer Drugs

Xin Zhang
Jing Zou
Jinghua Ning
Yanhong Zhao
Run Qu
Yuzhe Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1500968

223 views

Review

Accepted on 13 Feb 2025

The Multiple Biological Activities of Hyperoside: From Molecular Mechanisms to Therapeutic Perspectives in Neoplastic and Non-Neoplastic Diseases

in Pharmacology of Anti-Cancer Drugs

Weisong Zhang
Wang Rui
Rongqi Guo
ZhongQuan Yi
Yihao Wang
Hao Wang
Yangyang Li
Xia Li
Jianxiang Song

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1538601

Original Research

Accepted on 13 Feb 2025

Gut Microbiota-Derived Metabolite Phenylacetylglutamine Inhibits the Progression of Prostate Cancer by Suppressing the Wnt/β-Catenin Signaling Pathway

in Pharmacology of Anti-Cancer Drugs

Jing Lv
Shengkai Jin
Yuhua Zhou
Chaowei Fu
Yang Shen
Bo Liu
Jufa Li
Menglu Li
Yuwei Zhang
Ninghan Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1528058

Original Research

Published on 13 Feb 2025

Exploring skin adverse events and mechanisms of apalutamide using data mining algorithms and network pharmacology

in Pharmacology of Anti-Cancer Drugs

Yaqing Chen
Longzhuan Huang
Wenwei Li
Hangye Gu
Yong Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1517874

117 views

Mini Review

Accepted on 12 Feb 2025

Research Progress on Ferroptosis in Myelodysplastic Syndromes

in Pharmacology of Anti-Cancer Drugs

Yifan Yang
Jiongping Han
Yuxin Wei
Jiacheng Jin
Weiying Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1561072

Original Research

Accepted on 12 Feb 2025

SB218078 Inhibits Angiogenesis and Epithelial-Mesenchymal Transition in Breast Cancer

in Pharmacology of Anti-Cancer Drugs

Qianxue Wu
Jiawei Xu
Xin Tang
Jin Yu
Benhua Li
Yang Jun
Xiang Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1552707

Original Research

Accepted on 12 Feb 2025

Multi-omics analysis of the dynamic role of STAR+ cells in regulating platinum-based chemotherapy responses and tumor microenvironment in serous ovarian carcinoma

in Pharmacology of Anti-Cancer Drugs

Hongwei Lan
Helei Hou
Weihua Yan
Xiao Huang
Jiali Cui

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1545762

Original Research

Published on 11 Feb 2025

The clinical characteristics and implications of acute kidney injury during induction therapy for acute promyelocytic leukemia

in Pharmacology of Anti-Cancer Drugs

Kai Shen
Chenlu Yang
Jie Huang
Xiao Shuai
Ting Niu
Hongbing Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1540409

135 views

Original Research

Accepted on 10 Feb 2025

Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database

in Pharmacology of Anti-Cancer Drugs

Ye Hu
Linlin Zhang
Qineng Gong
Lei Huang
Cunlin Yin
Yang Miao
Hui Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1481114

Review

Accepted on 10 Feb 2025

Unleashing the Power of Peptides in Prostate Cancer Immunotherapy: Mechanism, facts and perspectives peptides for targeted therapy and immunological regulation against prostate cancer: Mechanism, facts and perspectives

in Pharmacology of Anti-Cancer Drugs

Xiaoya Li
Fang Yang
Meijing Wang
Xiaopeng Huang
Xin Zeng
Lu Zhou
Sixue Peng
Jingyi Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1478331

Editorial

Published on 10 Feb 2025

Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II

in Pharmacology of Anti-Cancer Drugs

Zhi-Bin Wang
De-Hua Liao
Guang Lei
Zhao-Qian Liu
Nayiyuan Wu
Jing Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1552652

191 views

Original Research

Published on 10 Feb 2025

The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

in Pharmacology of Anti-Cancer Drugs

Huihui Guo
Hongsheng Xie
Yuanyuan Huang
Junxiang Jia
Xiangfei Kong
Qingliang Yang
Shun Gai
Wenjun Li
Lu Bai
Lingli Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1532104

312 views

Review

Published on 10 Feb 2025

A comprehensive review of Schisandrin B’s preclinical antitumor activity and mechanistic insights from network pharmacology

in Pharmacology of Anti-Cancer Drugs

Yanhua Fang
Juan Pan
Piao Wang
Ruoyu Wang
Shanshan Liang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1528533

144 views

Navigation group

Articles

Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: A systematic review and network meta-analysis

Cyperotundone Promotes Chemosensitivity of Breast Cancer via SRSF1

Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinib

Identification of potential diagnostic targets and therapeutic strategies for anoikis-related biomarkers in lung squamous cell carcinoma using machine learning and computational virtual screening

The Multiple Biological Activities of Hyperoside: From Molecular Mechanisms to Therapeutic Perspectives in Neoplastic and Non-Neoplastic Diseases

Gut Microbiota-Derived Metabolite Phenylacetylglutamine Inhibits the Progression of Prostate Cancer by Suppressing the Wnt/β-Catenin Signaling Pathway

Exploring skin adverse events and mechanisms of apalutamide using data mining algorithms and network pharmacology

Research Progress on Ferroptosis in Myelodysplastic Syndromes

SB218078 Inhibits Angiogenesis and Epithelial-Mesenchymal Transition in Breast Cancer

Multi-omics analysis of the dynamic role of STAR+ cells in regulating platinum-based chemotherapy responses and tumor microenvironment in serous ovarian carcinoma

The clinical characteristics and implications of acute kidney injury during induction therapy for acute promyelocytic leukemia

Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database

Unleashing the Power of Peptides in Prostate Cancer Immunotherapy: Mechanism, facts and perspectives peptides for targeted therapy and immunological regulation against prostate cancer: Mechanism, facts and perspectives

Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II

The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

A comprehensive review of Schisandrin B’s preclinical antitumor activity and mechanistic insights from network pharmacology